Meckiff, 2021 - Google Patents
Evolution of the human CD4+ T cell response to Epstein-Barr virus infection-analysis of systemic and local immune responsesMeckiff, 2021
View PDF- Document ID
- 14978714021040909983
- Author
- Meckiff B
- Publication year
External Links
Snippet
CD4+ T cells are essential for overall control of human virus infections, yet their multiple roles remain ill-defined at the single cell level, and most studies have focused solely on analysis of those present in the circulation. Using Epstein-Barr virus (EBV)-specific human …
- 241000701044 Human gammaherpesvirus 4 0 title abstract description 287
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Halary et al. | Shared reactivity of Vδ2neg γδ T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells | |
| AU2008301240B2 (en) | A method for identifying antigen-specific regulatory T cells | |
| CN102388145A (en) | Compositions and methods for evaluating cytotoxicity of single cells | |
| Cooper et al. | Rapid GMP-compliant expansion of SARS-CoV-2–specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19 | |
| JP2017536843A (en) | Method for selecting T cell lines and donors for adoptive cell therapy | |
| CN107709351A (en) | Cytotoxic t cell epitope peptide for sars and application thereof | |
| Khalaf et al. | In vitro generation of cytotoxic T cells with potential for adoptive tumor immunotherapy of multiple myeloma | |
| US20090130144A1 (en) | Direct vaccination of the bone marrow | |
| US20200017586A1 (en) | Use of immune checkpoint modulators in combination with antigen-specific t cells in adoptive immunotherapy | |
| Brooks et al. | Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition | |
| JP2019110909A (en) | Epitope peptides of cytotoxic t lymphocyte and uses thereof | |
| Adamopoulou et al. | Human CD4+ T cells displaying viral epitopes elicit a functional virus-specific memory CD8+ T cell response | |
| Li Pira et al. | Generation of Cytomegalovirus (CMV)—Specific CD4 T Cell Lines Devoid of Alloreactivity, by Use of a Mixture of CMV—Phosphoprotein 65 Peptides for Reconstitution of the T Helper Repertoire | |
| Foster et al. | Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy | |
| Meckiff | Evolution of the human CD4+ T cell response to Epstein-Barr virus infection-analysis of systemic and local immune responses | |
| EP1146119A1 (en) | Method for obtaining specific T-lymphocytes, and for identifying unknown epitopes | |
| Haveman et al. | Selection of perforin expressing CD4+ adenovirus-specific T-cells with artificial antigen presenting cells | |
| Hamel et al. | Characterization of antigen‐specific repertoire diversity following in vitro restimulation by a recombinant adenovirus expressing human cytomegalovirus pp65 | |
| Kovacs | HIV1Uninfected Individuals Responses in HIV1Infected and Viral Specific CD8+ T Cell Memory Dendritic Cells and the Expansion of TNF {alpha} in the Activation of NF {kappa} B Ligand, and CD40 Ligand, Receptor Activator of Cooperation of TNF Family Members | |
| US12338458B2 (en) | Use of the IL-15/IL-15Rα complex in the generation of antigen-specific T cells for adoptive immunotherapy | |
| Jeras et al. | Induction/Engineering, Detection, Selection, and Expansion of Clinical‐Grade Human Antigen‐Specific CD8+ Cytotoxic T Cell Clones for Adoptive Immunotherapy | |
| Preece | Harnessing CD4+ T cell effectors for lymphoma therapy | |
| Kim et al. | Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: AN ew | |
| Gyurova | Phenotypic and functional dynamics of Cytomegalovirus-associated memory natural killer cells in the absence of cytomegalovirus infection | |
| Newhook | Natural killer cells generate memory-type responses to human cytomegalovirus-infected fibroblasts |